Trial Profile

Efficacy And Safety of BXCL501 Evaluated For At-Home Use In A Multisite Double-Blind Placebo-Controlled Trial For Agitation Associated With Schizophrenia And Bipolar Disorder

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 27 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dexmedetomidine (Primary)
Indications Agitation
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms SERENITY III
Sponsors BioXcel Therapeutics

Most Recent Events

18 Nov 2024 Planned End Date changed from 30 Mar 2025 to 5 Sep 2025.
18 Nov 2024 Planned primary completion date changed from 30 Mar 2025 to 5 Sep 2025.
18 Nov 2024 Status changed from active, no longer recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com